---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-288697"
form_type: "8-K/A"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2021-10-01T23:59:59+00:00"
generated_at: "2026-06-29T00:03:51.401967+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Lyell Immunopharma corrects Executive Chairman Klausner's resignation effective date to Oct 1, 2021

## Summary
- Original 8-K had a typo; resignation date corrected to October 1, 2021.
- Dr. Richard Klausner resigns as Executive Chairman and employee, effective October 1, 2021.
- No other changes made to the original disclosure.

## SEC filing metadata
- accession: 0001193125-21-288697
- form_type: 8-K/A
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2021-10-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000119312521288697/0001193125-21-288697-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000119312521288697/d239915d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-288697
- JSON: https://secwatch.observer/filing/0001193125-21-288697.json
- Plain text: https://secwatch.observer/filing/0001193125-21-288697.txt

## Key facts
- Executive change
  Richard Klausner resigned as Executive Chairman at Lyell Immunopharma, Inc..
  - Action: resigned
  - Role: Executive Chairman
  source text: On September 29, 2021, Dr. Klausner informed the Company that he will be resigning from his position as Executive Chairman of the Company and will no longer be an employee, effective October 1, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806952/000119312521288697/0001193125-21-288697-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.